Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rinvatercept · KER-065

Fusion protein · developed by Keros Therapeutics

Phase 2 Most advanced trial
KROS Developer
1 Registered trials

What is Rinvatercept?

Rinvatercept (KER-065) is an agent administered subcutaneously and studied in Duchenne muscular dystrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KER-065
Drug type
Fusion protein
Therapy area
Musculoskeletal
Developer
Keros Therapeutics, Inc. (KROS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
D674N274QK

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07704099 Phase 2 Duchenne Muscular Dystrophy Recruiting KROS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Duchenne Muscular Dystrophy

More from Keros Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KROS page.

Follow KROS, the company behind Rinvatercept

See KROS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KROS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.